Oxfam is closely watching the outcome of Novartis’ endless and highly
damaging challenge to Section 3(d) of India’s Patent Act. We are profoundly disappointed that Novartis has continued to pursue legal action against the Indian Government. Five years ago, hundreds of thousands of people called upon Novartis to drop its legal challenge against the Indian. Today, over 2 billion people still lack regular access to affordable medicines, and yet Novartis has persisted. Oxfam is seriously concerned that if Novartis succeeds, it will lead to long term and profound changes in India’s patent system that will undermine generic competition and access to affordable,low-cost medicines.
Blogroll
Link
- Argentinean Network of Women Living with HIV-AIDS
- Asia Pacific Network of People Living with HIV/AIDS
- bilaterals.org
- Cambodian People Living with HIV/AIDS Network (CPN+)
- Delhi Network of Positive People (DNP+)
- Essentialdrugs.org
- FACEBOOK PAGE: Stop the EU India Free Trade Agreement
- FTA Malaysia
- Health Action International – Asia Pacific
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS Unit
- MSF Access Campaign
- National Association of People Living with HIV and AIDS in Nepal (NAPN)
- Patent Opposition Database
- Public Citizen
- Stop Peru FTA
- Thai Network of People Living with HIV/Aids (TNP+)
- Third World Network
Take Action
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
-
Recent Posts
Categories
Pingback: A victory for Novartis could spell death for millions | All India Drug Action Network (AIDAN)